346 results about "Mrna expression" patented technology

The present invention discloses a strain of Lactobacillus paracasei that simultaneously activates immune regulation and antioxidant pathways to alleviate vaginitis, belonging to the field of microbial technology. The present invention screened and obtained a strain of Lactobacillus paracasei CCFM1316, which has the effect of repairing related symptoms such as immune disorders and oxidative damage caused by vaginitis, specifically embodied in: reducing cellular NF-κB mRNA expression and cell supernatant IL-1β content, improving mouse vaginal immune response, enhancing mouse vaginal antioxidant capacity, improving mouse vaginal pathological manifestations and reducing pathogenic bacteria load. It reduces the mouse vaginal Gardnerella load and improves mouse vaginal pathological manifestations; therefore, Lactobacillus paracasei CCFM1316 has great application prospects in products that improve and repair immune disorders and oxidative damage problems caused by vaginitis.

The invention discloses a grape seed source anti-inflammatory peptide, and belongs to the technical field of biological medicine. The amino acid sequence of the anti-inflammatory peptide is selected from any one of WGF, SHFGF, EGPFF, WAPR, SFYRAF, HFAFL, PGRF or FDSF. A BPS-induced RAW 264.7 mouse mononuclear macrophage inflammation model is established, and the eight synthetic peptides are found to significantly reduce the content level of NO in inflammatory cells and have an inhibition effect on secretion of inflammatory factors TNF-alpha and IL-6. A qRT-PCR (quantitative reverse transcription-polymerase chain reaction) experiment shows that the synthetic peptide can inhibit expression of mRNA (messenger Ribonucleic Acid) of p65, Tnf alpha, Il6, Il1b and Nos2, and can play an anti-inflammatory role by regulating and controlling an NF-kappa B signal channel. According to the method, the high-activity anti-inflammatory peptide is screened from the wine brewing byproduct grape seeds for the first time, and green and high-value utilization of the grape processing byproduct is realized.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention discloses an application of isorhamnetin in preparation of an anti-myocardial fibrosis medicine, and belongs to the technical field of medicines. The invention proposes that the isorhamnetin can effectively reduce myocardial tissue collagen deposition for the first time, and the medical application of the isorhamnetin is expanded. The isorhamnetin is used as the anti-myocardial fibrosis medicine, can effectively relieve the increase of mRNA expression levels of alpha-SMA, COL-1, COL-3, p53, PAI-1, IL-1beta and IL-6, and has the function of retarding myocardial fibrosis. The isorhamnetin is used as the active component of the anti-myocardial fibrosis medicine, the safety is high, the side effect is small, a novel anti-myocardial fibrosis treatment strategy is provided, and the application blank of the isorhamnetin in the field is filled.

The invention belongs to the technical field of biological genetic engineering, and relates to a high-risk myelodysplastic syndrome screening gene and a diagnostic kit thereof. The invention provides an application of detecting YTHDF2, METTL3 and NAT10 gene expression of bone marrow cells of high-risk MDS patients as a specific molecular marker for screening the high-risk myelodysplastic syndrome, and by detecting mRNA expression levels of the YTHDF2, METTL3 and NAT10 genes, the screening of the patients in the high-risk myelodysplastic syndrome is facilitated. Meanwhile, treatment and prognosis evaluation of patients with high-risk myelodysplastic syndromes can be better guided. Only the bone marrow fluid of the patient needs to be extracted and collected during bone marrow cytology examination of the patient, the patient compliance is good, the bone marrow fluid is selected from human bone marrow fluid mononuclear cells, the detection result is more accurate, and the method is suitable for clinical large-scale application.

A construction and use of an environmentally adaptive co-regulated mRNA nanodelivery system. By incorporating EACR molecules into mRNA nanoparticles, the microenvironment is remodeled to be suitable for robust and sustained mRNA expression, while tissue damage associated with the self-immunogenicity of mRNA drugs is avoided. The nanodelivery system is compatible with ionizable lipid nanoparticles, cationic liposomes, cationic nanoemulsions, and polymeric nanoparticles. The EACR molecules include: anti-inflammatory drugs, tyrosine kinases / adaptors, JAK / STAT and MAPK pathway inhibitors, nutrients and metabolites, membrane transporters / ion channels, phosphodiesterase and cellular stress inhibitors, and natural viral proteins. The therapeutic mRNAs may encode tumor, viral, or bacterial antigens, immunomodulatory factors, therapeutic antibodies, or functional proteins / enzymes, and can play a role in the fields of regenerative medicine, protein supplementation / replacement therapy, targeted gene editing, and immunotherapy.

The invention discloses a molecular chaperone synergistic blue-copper peptide and application thereof, belongs to the technical field of skin care, and particularly relates to a blue-copper peptide composition formed by compounding blue-copper peptide and N-acetylneuraminic acid, and the structure of the blue-copper peptide is that copper is connected to glycyl-L-histidyl-L-lysine; the blue copper peptide and the N-acetylneuraminic acid are mixed according to the mass ratio of 1: (0.1-1) for use, and further, phenylalanine derivatives can be added into the mixture for compounding. When the blue copper peptide composition obtained by the invention is applied to cells, the cell survival rate is high, the non-enzymatic glycosylation inhibition rate is good, and the expression of Elastin, Col-I and Col-IV mRNA in the cells is high. Therefore, the blue copper peptide composition disclosed by the invention is high in cell survival rate, good in non-enzymatic glycosylation inhibition rate and capable of improving the mRNA expression of Elastin, Col-I and Col-IV in cells, and the application of the blue copper peptide composition.

The invention discloses application of plant-derived glyceroglycolipid in preparation of an anti-inflammatory product, inflammation is RAW264.7 cell inflammatory response induced by LPS (lipopolysaccharide), and the plant-derived glyceroglycolipid can resist inflammation by inhibiting expression of inflammatory factors. By combining column chromatography with chromatographic analysis, efficient extraction, precise separation and structural identification of the plant GL are realized, and important technical support is provided for research of plant lipids. The plant GL can significantly inhibit inflammatory response of RAW264.7 macrophages, including reduction of LPS-induced cellular morphological change, down-regulation of inflammatory factor mRNA expression and reduction of CD86 expression level. The invention provides a solid molecular level theoretical basis for the application of the plant glycerol glycolipid in the development of anti-inflammatory functional foods and medicines.

Provided herein are, inter alia, agents (e.g., RNAi agents, dsRNA agents) comprising a sense strand and an antisense strand targeting CIDEB (e.g., hCIDEB); and methods of manufacturing and pharmaceutical compositions comprising the same. Further provided herein are methods of utilizing the agents (e.g., RNAi agents, dsRNA agents) including, e.g., methods of inhibiting or decreasing CIDEB expression (e.g., mRNA expression), methods of treating CIDEB associated diseases, and methods of treating liver diseases (e.g., MASH).

The present invention discloses the use of 3,4-dihydropsoralen in the preparation of a drug for preventing or treating rheumatoid arthritis. The present invention simulates RA by constructing TNF-a-induced SW982 cells. The results show that 3,4-dihydropsoralen (DP) can downregulate the mRNA expression of inflammatory factors, chemokines, and matrix degrading enzymes through the IL-17 signaling pathway, and affect the IL-17 signaling pathway and the NF-κB signaling pathway to jointly exert an anti-inflammatory effect, thereby effectively improving rheumatoid arthritis. This provides a theoretical basis for the application of 3,4-dihydropsoralen in the clinical treatment of rheumatoid arthritis and opens up new therapeutic drugs and approaches.

The invention provides a milk protein peptide which takes milk protein as a raw material and has the effects of promoting calcium absorption and improving bone health and application of the milk protein peptide. Specifically, milk protein peptide sequences, including YGGVSL and SQRY, are screened by adopting enzymolysis, sequence identification and molecular docking methods. The milk protein peptide is proved to have high calcium transport promoting capacity in the in-vitro intervention of Caco-2 cells, and the milk protein peptide is proved to have the capacity of promoting osteogenesis and inhibiting bone resorption in the in-vitro intervention of MC3T3-E1 mouse embryo osteoblasts. In animal experiments, by increasing the content of blood calcium and bone calcium, reducing the content of excrement calcium, improving mRNA expression of calcium ion channel protein, calcium binding protein and peptide transporter in intestinal tracts, enhancing the efficiency of calcium entering blood, promoting osteogenesis and inhibiting bone resorption, the milk protein peptide is comprehensively proved to have the capabilities of improving calcium resorption of organisms and improving bone health. The milk protein peptide has both functionality and nutrition, and has a wide application prospect in the aspect of bone health.

The invention relates to the technical field of biological medicine, and provides application of TRIM69 in preparation of a kit for auxiliary diagnosis of systemic lupus erythematosus. The kit assists in diagnosing systemic lupus erythematosus by detecting the TRIM69 level. Through the mRNA expression quantity of the TRIM69 and the expression quantity and / or concentration of the protein, the auxiliary diagnosis of the systemic lupus erythematosus is realized, and the TRIM69 as a biomarker has important values in the aspects of auxiliary diagnosis, disease activity monitoring, prognosis evaluation, diagnosis efficiency improvement and the like. Not only can a doctor be helped to recognize a high-risk patient earlier, but also a basis can be provided for individualized treatment, so that the long-term prognosis of the systemic lupus erythematosus patient is improved.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of Xianglian intestine decoction in preparation of a medicine for treating ulcerative colitis through a targeted TLR4 / NLRP3 / GSDMD channel. According to the invention, the TLR4 is determined as a key target, and experiments show that the active ingredients in the Xianglian intestine soup and the TLR4 have very strong binding affinity. In-vivo experiments prove that the Xianglian intestine soup down regulates the protein levels of TLR4, NLRP3 and GSDMD-N and the mRNA expression (Plt; 0.05) of IL-1beta and IL-18, so that the pyroptosis is inhibited. Furthermore, the Xianglian intestine decoction inhibits NLRP3 inflammasome activation and GSDMD-mediated pyroptosis by targeting TLR4 so as to relieve UC inflammation and intestinal barrier injury. The invention provides a mechanism insight for the clinical curative effect of the Xianglian intestine decoction for treating ulcerative colitis.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

The invention discloses an anti-inflammatory CAR-macrophage targeting FAP, a preparation method thereof and application of the anti-inflammatory CAR-macrophage in preparation of drugs for treating fibrosis diseases, and belongs to the technical field of biological medicines. The invention provides an FAP-specific chimeric antigen receptor, an mRNA expression vector of the FAP-specific chimeric antigen receptor, a His-labeled STING signal channel inhibitor and an mRNA expression vector of the His-labeled STING signal channel inhibitor. In-vivo and in-vitro macrophage editing can be effectively realized by delivering CAR mRNA and TRIM13mNRA through LNP, the ability of targeted phagocytosis of FAP positive cells is endowed, meanwhile, anti-inflammatory phenotypic polarization of macrophages is promoted, local inflammation is improved, and fibrosis progress driven by inflammation is synergistically restrained.

The invention belongs to the technical field of biological medicine, and particularly relates to a reagent for improving ovarian development and a preparation method and application thereof. The reagent for improving ovarian development is prepared by mixing the following raw materials in parts by weight: 20-30 parts of N-acetylcysteine; 5 to 10 parts of tranexamic acid; 3 to 8 parts of creatine; and 3000 parts of water. According to the reagent, the mRNA expression of PKD1P6 and follicle stimulating hormone receptors (FSHR) in ovarian tissues is up-regulated, the activity and functions of cumulus granular cells are enhanced, and apoptosis of the cumulus granular cells is inhibited, so that the effects of effectively promoting follicle development and inhibiting the apoptosis of the cumulus granular cells are achieved.

The invention discloses a preparation method of prune exosomes and application of the prune exosomes in regulation and control of pigment metabolism and skin cell inflammatory response, and the preparation method comprises the following steps: taking prune, washing, peeling, dicing, juicing, adding a compound enzyme preparation, centrifuging at 2,000 g for 20 min, carrying out trehalose-assisted ultracentrifugation, centrifuging at 12,000 g for 30 min, centrifuging at 40,000 g for 60 min, centrifuging at 120,000 g for 70 min, collecting precipitate PBS, re-suspending, and filtering to obtain the high-purity prune exosomes. It is proved for the first time that the prune exosome dose-dependently inhibits the melanin content and tyrosinase activity in B16F10 melanoma cells, the mRNA expression level of key inflammatory factors TNF-alpha, IL-1beta and IL-6 in TNF-alpha-induced Hacat cells is remarkably reduced, in addition, the inhibition effect of melanin can be amplified through an STAT3 channel by combining the prune exosome with luteolin, and the application of the prune exosome to the preparation of the anti-inflammatory drug is promoted. The polypeptide can be used for preparing a preparation for regulating pigment anabolism and skin-related inflammatory response, and a potential biological application value is exerted.

The present invention discloses a targeted knockout bovine FGFR1 The application of the sgRNA of the gene in constructing a bovine mammary epithelial cell line, wherein the sgRNA nucleotide sequence is shown in SEQ ID NO: 1. The mammary epithelial cell line obtained by constructing the sgRNA of the present invention through CRISPR / Cas9 technology, FGFR1 Protein expression was significantly downregulated, and knockout FGFR1 The gene expression had no significant effect on the viability and proliferation of mammary epithelial cells. PCNA 、 Cyclin D1 、 Cyclin E1 There was no significant change in the mRNA expression of the genes related to milk protein synthesis (such as CSN1S1 、 CSN2 、 CSN3 、 EFL5 ), lactose synthesis-related genes ( GLUT1 and HKⅡ ) and milk fat synthesis-related genes ( SCD‑1 ) were significantly decreased, providing a basis for in-depth analysis FGFR1 It provides key tools for the regulatory mechanisms of mammary epithelial cell proliferation, lactation synthesis and other biological behaviors.

The invention discloses antisense oligonucleotides for reducing XDH gene expression in a targeted manner and application of the antisense oligonucleotides, and belongs to the technical field of biological medicines. The antisense oligonucleotide mediates the degradation of the target mRNA through an RNase H (RNase H) dependent cleavage mechanism, and the mRNA expression of the XDH gene is horizontally knocked down after transcription; the antisense oligonucleotide molecule has a specific nucleic acid sequence, is combined with chemical modification design, can specifically bind XDH mRNA molecules in a targeting manner, promote XDH mRNA degradation and inhibit XDH protein synthesis, so that the expression level of XDH in cells is reduced, uric acid synthesis is reduced, the purpose of reducing uric acid is finally achieved, and cell experiments and animal model tests show that the antisense oligonucleotide molecule has a good application prospect. The antisense oligonucleotide molecule disclosed by the invention has a good uric acid reducing effect, and is long in drug effect duration and high in drug safety.

The invention discloses a 5 'UTR sequence and application thereof in improving mRNA translation efficiency, and belongs to the technical field of biology, the designed 5' UTR sequence has an excellent mRNA expression promoting function, and compared with a common HBA1 gene 5 'UTR, the FLuc mRNA expression level fused with the 5' UTR can be improved to 2-3.5 times.

The application relates to the technical field of biological medicine and fundus disease treatment, in particular to application of Acbd3 in treatment of fundus diseases. It is found that the mRNA expression level and the protein expression level of Acbd3 in the retina of a fundus disease model mouse are significantly higher than those of a control group. After an Acbd3 inhibitor is used, the inflammatory reaction and neuron apoptosis in the retina of the fundus disease model mouse are significantly relieved, abnormal activation of Muller cells and microglia cells can be reduced, and a damaged blood-retina barrier can be repaired.

The invention discloses bifidobacterium longum subsp. Infantis for regulating intestinal motility and aquaporin and application of the bifidobacterium longum subsp. Infantis, and belongs to the technical field of microorganisms. According to the invention, the bifidobacterium longum subsp. Infantis CCFM1269 is screened, and the bifidobacterium longum subsp. Infantis CCFM1269 has the effects of intestinal motility and aquaporin, specifically, the defecation frequency is reduced, and the water content of excrement and the small intestine propulsion rate are reduced. The intestinal motility abnormality is relieved by reducing the levels of neurotransmitters 5-HT, SP and VIP, and the intestinal moisture absorption and secretion are regulated by improving the mRNA expression of aquaporin AQP4 and AQP8. Meanwhile, the intestinal flora is adjusted by improving the diversity of the intestinal flora, and the content of propionic acid and butyric acid in excrement is increased.

To provide agents for promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production by finding substances having excellent activity in promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production.SOLUTION: An epidermal keratinocyte growth promoting agent of the invention comprises one or more effective ingredients selected from the group consisting of 2-ketoglutaric acid, 2-isopropyl malate, inosine 5'-monophosphoric acid, succinic acid, malic acid and pyruvic acid. Also, a filaggrin mRNA expression promotor, a serine palmitoyltransferase mRNA expression promotor, an involucrin expression promotor of the invention comprise, as an effective ingredient, 2-ketoglutaric acid. Further an ATP production promotor of the invention comprises 2-isopropyl malate as an effective ingredient.SELECTED DRAWING: None

The application provides a group of small interfering RNAs (siRNAs) targeting pyroptosis-related inflammatory reaction genes and application thereof. The pyroptosis-related inflammatory reaction genes include IL1A, IL1B, IL6, HMGB1, S100A8, S100A9 and BACH1. The application designs and synthesizes specific siRNA sequences for the above genes, and verifies that the siRNAs can efficiently and specifically inhibit the mRNA expression level of the corresponding genes through cell transfection and real-time fluorescent quantitative PCR. The application also provides a composition containing the siRNAs, a pharmaceutical composition and application thereof in the preparation of a drug for treating diseases mediated by pyroptosis-related inflammatory reaction genes (especially inflammatory diseases). The siRNAs and the composition thereof provide a new effective strategy for treating diseases related to excessive activation of pyroptosis-related inflammatory reactions, and have a wide application prospect.

The invention relates to application of a targeted intervention strategy based on a TRIM25-SNRK regulatory axis in treatment of non-small cell lung cancer. The nucleotide sequences of the mRNA of the TRIM25 gene and the mRNA of the SNRK gene are respectively as shown in SEQ ID NO.1 to SEQ ID NO.2. According to the invention, it is found for the first time that the combined targeting TRIM25-SNRK regulatory axis has a more significant cancer inhibition effect in the cell proliferation and migration process of the non-small cell lung cancer compared with single interference of TRIM25 expression level or transfection of exogenous SNRK mRNA expression plasmids. The siTRIM25 and SNRK-OE combination strategy designed by the invention can specifically knock down the level of TRIM25 mRNA and up-regulate the level of SNRK mRNA at the same time, and compared with the condition of singly transfecting siTRIM25 or SNRK-OE, a cell function experiment shows that the combination strategy has a more effective anti-tumor effect. Therefore, the TRIM25-SNRK regulation axis can be used as an intervention target to be applied to research, development and preparation of non-small cell lung cancer antitumor drugs.

The application discloses a UTR element and application thereof, wherein the UTR element is selected from a 3'UTR sequence shown in SEQ ID NO: 7 or 8. The UTR element can prolong mRNA expression and stability, and significantly improve the immunization effect of a vaccine.

The invention discloses application of an mRNAs marker in early diagnosis of lung signet-ring cell carcinoma and a kit. The marker is a combination of C1QA, CRISPLD2, ROBO4, SPARCL1, SFTPB, LAMC3, FN1, EMP1, CD68, THBS1, PRG4, ICAM1, PODXL, KDM6B, ENPP2, KLF10 and THBD (tetrahydrofuran). According to the invention, FFPE cancer tissue of a patient with primary pulmonary signet ring cell carcinoma diagnosed by an existing detection means in clinic is used as a sample, para-carcinoma tissue is used as a control sample, mRNA expression profiles of the cancer tissue and the control tissue are detected by adopting an RNA sealing technology, and 17 differentially expressed mRNA markers are found by applying statistics and a machine learning method. Based on the 17 found markers, a risk scoring model with high sensitivity and specificity is constructed, and the sensitivity gt of the model to early-stage lung signet-ring cell carcinoma diagnosis; the specificity is gt; 89%.

The invention discloses a siRNA molecule for interfering sheep TBXT gene expression in primary culture of sheep bone marrow mesenchymal stem cells and application of the siRNA molecule, and relates to the technical field of molecules. According to the invention, a method for in-vitro targeting sheep TBXT gene interference siRNA transfected cells is established by synthesizing a specific targeting combination sheep TBXT gene small fragment sequence, and the mRNA expression level of the TBXT gene of sheep bone marrow mesenchymal stem cells can be effectively interfered. A further research proves that the proliferation efficiency of the sheep bone marrow mesenchymal stem cells is obviously reduced after the TBXT gene is interfered. The TBXT gene is helpful for researching the biological function of the TBXT gene participating in embryonic caudal vertebra development regulation, and has good application value for researching the molecular mechanism of the sheep tail type character.

The present invention provides a prognostic scoring system for hepatocellular carcinoma based on PUS family genes and its application. The input variables of the prognostic scoring system for hepatocellular carcinoma based on PUS family genes include the expression status coefficient, Gini coefficient and integrated risk coefficient of the PUS family genes in the dataset; the expression status coefficient is determined according to the relationship between the mRNA expression level of the PUS family genes and the average measured value. The prognostic scoring system for hepatocellular carcinoma based on PUS family genes associates the importance of 5 HCC-related PUS family genes with the prognosis and clinical characteristics of HCC patients. In different HCC datasets, there are significant differences in overall survival rates among patients with different scores. The higher the score, the lower the overall survival rate. The prognostic scoring system for hepatocellular carcinoma can be effectively used for the evaluation of the prognosis of HCC patients and has certain specificity and sensitivity in clinical practice.

The present invention relates to a method for immunological evaluation of mRNA expression levels. The problem addressed by the present invention is to develop a method capable of simply and accurately quantifying and analyzing a protein in immunology so as to be able to compare and evaluate the function and effect of two or more mRNAs having different sequences in the form of the expression level of a protein encoded by mRNA. Labeled mRNAs are prepared, in each labeled mRNA, a labeled nucleotide encoding the same labeled peptide is linked to the terminus of the mRNA. The respective expression levels of the labeled polypeptides expressed from the labeled mRNA are quantified using the same antibody against the labeled peptides.